Question 1

What has ipamorelin actually been compared against?

Accepted Answer

Four things, and none of them is what most searches ask about. The 1998 paper that introduced ipamorelin tested it against two older compounds of its family, GHRP-6 and GHRP-2, and used the brain's own releasing hormone as a reference. A rat study the same year compared it with two well-known hexapeptides, GHRP-2 and GHRP-6, in the male rat, hexapeptides being chains of six amino acids. A 2009 study then set it against growth hormone itself, in rats given a muscle-wasting steroid. In that experiment five groups of rats were included, two of which received either growth hormone or ipamorelin on top of the steroid. The fourth comparator is placebo, in the one human trial. Every other pairing on this page rests on separate literatures read side by side rather than on a shared experiment. That distinction decides how much weight each section below can bear, and it is worth keeping in view whenever two compounds appear in neighbouring columns of a chart.

Question 2

MK-677 vs ipamorelin: what has been measured?

Accepted Answer

They have been reviewed together, but never tested together, among the research behind this page. A 2026 scoping review set out to summarise the evidence on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]). It reports each compound on its own rather than one against another. A 2020 review of these compounds in men with low testosterone does the same, listing the ones it covers as sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. Ibutamoren is the chemical name for MK-677, and the scoping review spells out that link by writing MK-677 [ibutamoren] in its search terms. So the two sit in the same reviews, under the same heading, without a shared measurement. Which raises growth hormone more, which changes body composition more, and which a person tolerates better are all unanswered here, rather than answered in favour of one. MK-677's own trial record is set out on the MK-677 overview.

Question 3

Does MK-677 carry more documented risk than ipamorelin?

Accepted Answer

More documented risk, yes, which is not the same as more risk. The 2026 scoping review that covers both singles one out, reporting that some peptides such as MK-677 were associated with significant risks including congestive heart failure. Congestive heart failure means the heart failing to keep up with the body's needs, with fluid building up as a result. Ipamorelin has no matching entry, and the reason matters: its human record is one week of infusions in hospital patients plus single infusions in healthy men, far too little exposure for a harm like heart failure to surface. The same review applies one finding to the whole group: documented risks include cardiovascular complications and metabolic dysfunction such as insulin resistance. That sentence covers ipamorelin as much as MK-677. Read the gap between them as a gap in how much each has been studied, rather than evidence that ipamorelin is the gentler of the two. The ipamorelin harm record is weighed in full on the Ipamorelin safety page.

Question 4

MK-677 vs ipamorelin with CJC-1295: is there a comparison?

Accepted Answer

None among the research behind this page, in people or animals. The three-way question, whether MK-677 alone does more or less than the injected pair, combines two gaps: MK-677 has not been compared with ipamorelin, and the pair has not been compared with anything. What the pair does have is a single animal result, and it belongs to a different page. A 2026 primer reports that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss. That experiment, and what it is worth, is taken apart on the CJC-1295 comparison page rather than repeated here. The scoping review that covers all three compounds reaches a verdict that applies to every option in this question: the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials. Comparing two unsubstantiated options does not produce a winner, because there is no measured outcome to rank them on.

Question 5

What's better, ipamorelin or tesamorelin?

Accepted Answer

No study among the research behind this page has compared them, so neither can be called better. What separates them is a decision by a regulator, rather than a result from a shared trial. Tesamorelin finished its path to approval. A 2026 primer records that tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence. Lipodystrophy means fat stored in the wrong places in the body. A 2026 review in Sports Medicine lists it by its brand name, tesamorelin (Egrifta), among approved and unapproved peptides. Ipamorelin did not finish. Its one controlled trial, after bowel surgery, found no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses. So one has an approval for one named condition and no muscle or joint evidence, and the other has a missed trial in a gut condition. Neither fact tells you which does more for a healthy adult. Tesamorelin's side of the comparison is set out on the Tesamorelin comparison page.

Question 6

Ipamorelin vs GHRP-6: how did they compare?

Accepted Answer

Closely, for growth hormone release, and this is the most thorough head-to-head record ipamorelin has. In cells taken from rat pituitary glands, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6. Potency is how little is needed for an effect, and efficacy is how large the effect can get. The pattern held in whole animals. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6, and in pigs the authors wrote again, this was very similar to GHRP-6. The difference came in the stress hormones, and that comparison is what made ipamorelin known. In that animal work on pigs, administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Ipamorelin did not, and that result is examined on the Ipamorelin overview. Equal growth hormone release with a narrower hormonal footprint is a real pharmacological difference, measured in rats and pigs rather than in people.

Question 7

Ipamorelin vs GHRP-2: what separated them?

Accepted Answer

Potency against maximum response in pigs, and absorption through the nose in rats. The 1998 pig experiments found that GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma). In plain words, GHRP-2 needed a smaller amount to produce an effect, but its largest growth hormone response was smaller than the response to ipamorelin. The rat absorption study pointed in the opposite direction, because when the compounds were sprayed into the nose, higher bioavailabilities of approximately 50% were determined for NNC 26-0235, NNC 26-0194 and GHRP-2, against roughly a fifth for ipamorelin. Bioavailability, the share of an amount that reaches the bloodstream, is therefore where GHRP-2 came out ahead. Each compound therefore comes out ahead on a different measure, and neither measure is an outcome a person would notice. A comparison that divides this way is why a single ranking of these compounds misleads more than it informs.

Question 8

How does ipamorelin's clearance compare with its relatives?

Accepted Answer

Ipamorelin stayed in the blood longer than its closest relative, in rats. The 1998 study reported that ipamorelin differed markedly from the other peptides investigated, demonstrating a systemic plasma clearance 5-fold lower than that of GHRP-6. Clearance is the rate at which the body removes a compound, so a lower figure means it lingers. The exit routes differed as well. In those rats, ipamorelin was mainly excreted in the urine, whereas GHRP-6 was predominantly excreted in the bile, and two sister compounds from the same programme also showed high biliary excretions, biliary meaning through the liver into bile. What this does not show is a longer effect. Slower clearance in a rat changes how long the molecule circulates, while the 1999 human study recorded an exponential decline to negligible GH concentration at all doses within hours of each infusion. Clearance compares how the body handles each molecule, which is different from comparing what each one does for the person receiving it.

Question 9

Ipamorelin vs growth hormone: what did the steroid-rat study find?

Accepted Answer

Growth hormone performed better, and the amounts were not matched. The 2009 study gave rats prednisolone, a steroid that breaks down body protein, and then added one of two compounds: (4) prednisolone and GH (1 mg x kg(-1) x day(-1)) (5) prednisolone and Ipamorelin (0.5 mg x kg(-1) x day(-1)). Growth hormone was therefore administered at twice the amount by weight. Both counteracted the steroid's protein loss, and the authors concluded that the wasting was opposed by either compound, though at the doses given less efficiently by the latter, the latter being ipamorelin. The phrase at the doses given carries the weight here: with growth hormone at double the amount, the experiment cannot distinguish whether ipamorelin is intrinsically weaker or was simply given less. It demonstrates that in steroid-treated rats over one week, this amount of growth hormone outperformed this amount of ipamorelin, which is narrower than a verdict that one is superior. What the approved forms of growth hormone cover is set out on the HGH overview.

Question 10

Is ipamorelin the same as sermorelin or CJC-1295?

Accepted Answer

No, and the difference lies in which door each one uses. A 2026 critical review of peptides in sport sorts the field into growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin). Sermorelin and CJC-1295 copy the brain's own signal to release growth hormone. Ipamorelin works through a different door, the one the hunger hormone ghrelin uses. The mix-up is easy to make, since other reviews put them all under one heading. A 2026 review for bone doctors writes of growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 as a single family. Both ways of sorting them are fair. All of them aim at more growth hormone, and they get there by different routes. The 1998 paper measured the practical result of that difference. It found ipamorelin's selectivity similar to that displayed by GHRH, GHRH being the natural releasing hormone that sermorelin and CJC-1295 imitate. So ipamorelin acts like the other group in how narrow its effect is, while it reaches the gland by its own door.

Question 11

Can ipamorelin be combined with other compounds?

Accepted Answer

Pharmacies have combined it, and nobody among these sources has measured the result. The FDA recall record holds several mixed vials, among them SERMORELIN ACETATE 9MG/IPAMORELIN 9MG - LYOPHILIZED and CJC-1295 4MG/IPAMORELIN 4MG VIAL 4MG/4MG INJECTABLE. Each was withdrawn for lack of assurance of sterility, which says nothing about the pairing itself. The logic people give for these pairings is that a releasing-hormone copy and a ghrelin-route compound reach the pituitary by different doors. That is a reason to expect more growth hormone, but it is not a measurement. A 2026 review of peptides in ageing groups the two under growth hormone modulation (CJC-1295, ipamorelin) and still lists the effects of combining therapies among its open questions. The sermorelin pairing is examined further on the Sermorelin comparison page, and the CJC-1295 pairing, which has one mouse result, on the CJC-1295 comparison page. A combination inherits the gaps of both halves rather than closing either.

Question 12

Ipamorelin vs IGF-1 LR3: how do they differ?

Accepted Answer

They act at different points of one hormonal chain, and none of the sources behind this page mentions IGF-1 LR3 by name. Ipamorelin works at the top of that chain: a 2020 review describes it and its relatives as potent GH and IGF-1 stimulators, where IGF-1, insulin-like growth factor 1, is the growth messenger that rises downstream of growth hormone. IGF-1 LR3, as its name indicates, is a version of that downstream messenger itself. The ipamorelin literature describes only the top of the chain. A 2026 orthopaedic review states that compounds of ipamorelin's kind activate IGF-1 signaling and satellite cell repair, satellite cells being the repair cells of muscle. The same review records there is a current lack of clinical trials behind that description. The difference is therefore one of mechanism rather than of measured outcome, since one raises the body's own signal indirectly and the other enters further down the chain. Without a shared study there is no basis to say which does more or which carries more risk, and the CJC-1295 family's comparison with IGF-1 LR3 is set out at the CJC-1295 comparison page.

Question 13

How does ipamorelin's human evidence compare with its family?

Accepted Answer

It is unusual in one way and ordinary in another. Unusually, ipamorelin reached a randomised, placebo-controlled trial in patients, which many compounds sold beside it never did. A 2026 scoping review describes the general state of this group, finding that human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs. Ordinarily, that trial asked about the gut and missed its goal. The 2020 review of these compounds in men states that current data on their clinical efficacy largely remain lacking, and that applies to ipamorelin as much as to the others it covers. Tesamorelin stands apart from all of them with an approval, though only for one condition. MK-677 carries a flagged heart risk in the 2026 scoping review. Ipamorelin has a narrower hormone profile in pigs and a negative trial in people. Ranking them would mean treating a regulatory decision, a risk signal and an animal finding as one measure.

Question 14

What would a fair comparison need?

Accepted Answer

It would need the same people, the same outcome, the same route and matched amounts. No study among the research behind this page has done that for ipamorelin against MK-677, tesamorelin or IGF-1 LR3. Each part matters, because people respond in different ways: the 1999 volunteer study found that inter-individual variability of the PD parameters was larger than that of the PK parameters, meaning hormone responses varied more between men than blood levels did. Route matters just as much. Every human ipamorelin figure came from a drip into a vein, while most comparisons people draw assume a shot under the skin. The scoping review of this group notes that significant heterogeneity existed in dosing and route of administration, which makes figures from different studies hard to line up. A 2026 review of peptides in ageing names the kind of work required, stating that investigational peptides require rigorous validation through well-designed clinical trials. Until such a trial exists, every ranking of these compounds is pieced together from separate studies rather than measured in one.

Ipamorelin comparisons and stacks